NCT02129556View on ClinicalTrials.gov

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 4, 2017

Study Completion Date

August 4, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

MK-3475

The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.

Trial Locations (11)

435

Istituto Europeo di Oncologia, Milan

1000

Jules Bordet Institute, Brussels

1090

Medical University of Vienna, Vienna

4000

CHU Sart Tilman, Liège

59100

Azienda USL4 Prato, Prato

69008

Centre Leon Berard, Lyon

94805

Institut Gustave Roussy, Villejuif

Unknown

Peter MacCallum Cancer Centre, East Melbourne

Westmead Hospital, Westmead

Institut de Cacérologie de l'OUEST, Angers

Institut Bergonie, Bordeaux

Sponsors
All Listed Sponsors
collaborator

Breast International Group

OTHER

lead

ETOP IBCSG Partners Foundation

NETWORK

NCT02129556 - Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter